Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registrySalomon M. Stemmer, Noa Ben-Baruch, Nicky Liebermann et al.|npj Breast Cancer|2017Cited by 87
Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registrySalomon M. Stemmer, Nicky Liebermann, Mariana Steiner et al.|npj Breast Cancer|2017Cited by 70
Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapySalomon M. Stemmer, David Geffen, Mariana Steiner et al.|npj Breast Cancer|2019Cited by 30
Abstract P5-08-02: Real-life analysis evaluating 1594 N0/Nmic breast cancer patients for whom treatment decisions incorporated the 21-gene recurrence score result: 5-year KM estimate for breast cancer specific survival with recurrence score results ≤30 is >98%Salomon M. Stemmer, Nicky Liebermann, M. Steiner et al.|Cancer Research|2016Cited by 23
First prospectively-designed outcome study in estrogen receptor (ER)+ breast cancer (BC) patients (pts) with N1mi or 1-3 positive nodes in whom treatment decisions in clinical practice incorporated the 21-gene recurrence score (RS) resultSalomon M. Stemmer, Noa Ben-Baruch, M. Steiner et al.|Annals of Oncology|2016Cited by 3